Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.

CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
PMID: 30758670 [PubMed - as supplied by publisher]

Source: Clinical Lung Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Melling N, Bachmann K, Hofmann B, El Gammal AT, Reeh M, Mann O, Moebius C, Blessmann M, Izbicki JR, Grupp K Tags: J Cancer Res Clin Oncol Source Type: research